Show simple item record

dc.contributor.authorHusa AP
dc.contributor.authorMoilanen J
dc.contributor.authorMurray GK
dc.contributor.authorMarttila R
dc.contributor.authorHaapea M
dc.contributor.authorRannikko I
dc.contributor.authorBarnett JH
dc.contributor.authorJones PB
dc.contributor.authorIsohanni M
dc.contributor.authorRemes AM
dc.contributor.authorKoponen H
dc.contributor.authorMiettunen J
dc.contributor.authorJääskeläinen E
dc.date.accessioned2017-04-12T10:22:47Z
dc.date.available2017-04-12T10:22:47Z
dc.date.issued2016
dc.identifier10.1016/j.psychres.2016.10.085fi_FI
dc.identifier.issn0165-1781
dc.identifier.urihttps://erepo.uef.fi/handle/123456789/1582
dc.descriptionArticle
dc.description.abstractThis naturalistic study analysed the association between cumulative lifetime antipsychotic dose and cognition in schizophrenia after an average of 16.5 years of illness. Sixty participants with schizophrenia and 191 controls from the Northern Finland Birth Cohort 1966 were assessed at age 43 years with a neurocognitive test battery. Cumulative lifetime antipsychotic dose-years were collected from medical records and interviews. The association between antipsychotic dose-years and a cognitive composite score based on principal component analysis was analysed using linear regression. Higher lifetime antipsychotic dose-years were significantly associated with poorer cognitive composite score, when adjusted for gender, onset age and lifetime hospital treatment days. The effects of typical and atypical antipsychotics did not differ. This is the first report of an association between cumulative lifetime antipsychotic dose and global cognition in midlife schizophrenia. Based on these data, higher lifetime antipsychotic dose-years may be associated with poorer cognitive performance at age 43 years. Potential biases related to the naturalistic design may partly explain the results; nonetheless, it is possible that large antipsychotic doses harm cognition in schizophrenia in the long-term.fi_FI
dc.language.isoENfi_FI
dc.publisher© Elsevier BVfi_FI
dc.relation.ispartofseriesPSYCHIATRY RESEARCH;
dc.relation.urihttp://dx.doi.org/10.1016/j.psychres.2016.10.085fi_FI
dc.rightsCC BY-NC-ND https://creativecommons.org/licenses/by-nc-nd/4.0/
dc.subjectPsychosisfi_FI
dc.subjectCognitionfi_FI
dc.subjectTreatmentfi_FI
dc.subjectCross-sectionalfi_FI
dc.subjectAdverse effectfi_FI
dc.titleLifetime antipsychotic medication and cognitive performance in schizophrenia at age 43 years in a general population birth cohortfi_FI
dc.typehttp://purl.org/eprint/type/JournalArticle
dc.description.versionfinal draftfi_FI
dc.contributor.departmentSchool of Medicine / Clinical Medicine
uef.solecris.id45509585
eprint.statushttp://purl.org/eprint/status/PeerReviewedfi_FI
dc.type.publicationinfo:eu-repo/semantics/article
dc.rights.accessrightsElsevier BV
uef.citationinfo.issueVolume 247, January 2017
uef.citationinfo.pages130-138
dc.relation.doi10.1016/j.psychres.2016.10.085
dc.description.reviewstatushttp://purl.org/eprint/status/PeerReviewed
dc.format.pagerange130-138
dc.relation.issn0165-1781
dc.relation.issueVolume 247, January 2017
dc.rights.accesslevelopenAccess


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record